Nejm.org: Anthony J. Furlan, M.D., Mark Reisman, M.D., Joseph Massaro, Ph.D., Laura Mauri, M.D., Harold Adams, M.D., Gregory W. Albers, M.D., Robert Felberg, M.D., Howard Herrmann, M.D., Saibal Kar, M.D., Michael Landzberg, M.D., Albert Raizner, M.D., and Lawrence Wechsler, M.D. for the CLOSURE I Investigators N Engl J Med 2012; 366:991-999 – March 15, 2012. […]
Plosone: Vivian Welch1,2*, Mark Petticrew3, Erin Ueffing4, Maria Benkhalti Jandu2, Kevin Brand5, Bharbhoor Dhaliwal2, Elizabeth Kristjansson6, Janet Smylie7,8, George Anthony Wells9,10, Peter Tugwell1,2,11 – March 13, 2012. Abstract Top Introduction Tackling health inequities both within and between countries remains high on the agenda of international organizations including the World Health Organization and local, regional and national […]
physorg.com: March 13th, 2012. Stroke and other diseases and injuries to the brain are often followed by inflammation, caused by a reaction of the body’s immune system. This reaction has been seen as something that must be combated, but perhaps the immune system could in fact help with recovery following a stroke. A major new EU […]
Onlinelibrary.wiley.com: Wen-tong Fang MD1, Hong-jian LI MD2, Haibo Zhang MD1, Su Jiang BD1 – March 9, 2012. Summary Aims: To examine whether statins can reduce the risk of atrial fibrillation (AF). Background: The use of statins had been suggested to protect against AF in some clinical observational and experimental studies but has remained inadequately explored. Methods: Meta analysis of […]
Etsmjournal.com: Bernd Kallmunzer, Stefan Schwab and Rainer Kollmar – March 7, 2012. Abstract (provisional) Background Hypothermia is neuroprotective in experimental stroke and may extend the so far limited therapeutic time window for thrombolysis. Therefore, hypothermia of 34degreesC and its effects on delayed thrombolysis including reperfusion-associated injury were investigated in a model of thromboembolic stroke (TE). Methods Male Wistar rats (n=48) […]
Meta-analysis of Noninferiority Randomized Controlled Trials Archinte.ama-assn.org: Ken Uchino, MD; Adrian V. Hernandez, MD, PhD – March 12, 2012. Background The original RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran etexilate vs warfarin in patients with atrial fibrillation. We systematically evaluated the risk of […]
Schattauer.de: A. Banerjee (1), D. A. Lane (1), C. Torp-Pedersen (2), G. Y. H. Lip (1), (1) University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK; (2) Department of Cardiology, Copenhagen University Hospital – March 12, 2012. Gentofte, Denmark Summary The concept of net clinical benefit has been used to quantify the balance between risk […]
Time to Finally Open Our Eyes! Content.onlinejacc.org: Michele Coceani, MD* * Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi 1, 56124 Pisa, Italy (Email: michecoc@ftgm.it). March 12, 2012. I read with interest the study by Saksena et al. (1) recently published in the Journal. Analyzing data from the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial, the authors report that atrial fibrillation […]
Stroke.ahajournals: The Bern Stroke Project Urs Fischer, MD, MSc; Marie-Luise Mono, MD; Marcel Zwahlen, PhD; Krassen Nedeltchev, MD; Marcel Arnold, MD; Aekatarini Galimanis, MD; Sabine Bucher, MSc; Oliver Findling, MD; Niklaus Meier, MD; Caspar Brekenfeld, MD; Jan Gralla, MD, MSc; Regula Heller, MNSc, MPH; Beatrice Tschannen, MPH; Heinz Schaad, MD; Gabriel Waldegg, MD; Thomas Zehnder, MD; […]
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF The Lancet Neurology, Early Online Publication, 7 March 2012. Summary Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). […]
